Given the observations in this study and previous reports, for AD associated with IKAROS deficiency, even refractory AD such as SLE, there is a possibility that treatment is unnecessary after hypogammaglobulinemia onset. This evidence concerns the gene IKZF1 and agammaglobulinemia.